GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Milestone Scientific Inc (AMEX:MLSS) » Definitions » Debt-to-EBITDA

Milestone Scientific (Milestone Scientific) Debt-to-EBITDA : -0.05 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Milestone Scientific Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Milestone Scientific's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.11 Mil. Milestone Scientific's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.28 Mil. Milestone Scientific's annualized EBITDA for the quarter that ended in Dec. 2023 was $-7.79 Mil. Milestone Scientific's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.05.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Milestone Scientific's Debt-to-EBITDA or its related term are showing as below:

MLSS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.13   Med: -0.06   Max: 0
Current: -0.06

MLSS's Debt-to-EBITDA is ranked worse than
100% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.25 vs MLSS: -0.06

Milestone Scientific Debt-to-EBITDA Historical Data

The historical data trend for Milestone Scientific's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Milestone Scientific Debt-to-EBITDA Chart

Milestone Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.13 -0.08 -0.06 -0.06

Milestone Scientific Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.09 -0.05 -0.07 -0.05

Competitive Comparison of Milestone Scientific's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Milestone Scientific's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Milestone Scientific's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Milestone Scientific's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Milestone Scientific's Debt-to-EBITDA falls into.



Milestone Scientific Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Milestone Scientific's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.114 + 0.282) / -6.956
=-0.06

Milestone Scientific's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.114 + 0.282) / -7.792
=-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Milestone Scientific  (AMEX:MLSS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Milestone Scientific Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Milestone Scientific's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Milestone Scientific (Milestone Scientific) Business Description

Traded in Other Exchanges
N/A
Address
425 Eagle Rock Avenue, Roseland, NJ, USA, 07068
Milestone Scientific Inc is engaged in pioneering proprietary, technological systems, and solutions for the medical and dental markets. It develops, manufactures, markets and sells the computer-controlled system for the improved and painless delivery of local anesthetic. The system is marketed in dentistry under the trademark CompuDent and in medicine under the trademark CompuMed. In addition, the company provides The Wand, a handpiece that allows dentists to provide painless injections for virtually various dental procedures, including routine cleanings and fillings, as well as implants, root canals, and crowns. The Company conducts its business through two reportable segments: Dental and Medical. Geographically all the operations of the firm function through the region of the U.S.
Executives
Peter J Milligan officer: President 1650 TYSONS BOULEVARD, SUITE 1700, MCLEAN VA 22102
Neal I Goldman director 170 SOUTHPORT DRIVE, MORRISVILLE NC 27560
Leslie Bernhard director C/O ADSTAR, INC., 488 S. ROYAL LANE, COPPELL TX 75019
Benedetta I Casamento director 200 CAMPUS DRIVE, FLORHAM PARK NJ 07932
Leonard Osser director, 10 percent owner, officer: CEO
Leonard M Schiller director
Scott L. Kahn officer: Chief Financial Officer 425 EAGLE ROCK AVENUE, SUITE 403, ROSELAND NJ 07068
Giandomenico Trombetta director, 10 percent owner CORSO VENEZIA 44, MILAN L6 20121
Joseph D'agostino officer: CFO & COO C/O MILESTONE SCIENTIFIC INC., 220 SOUTH ORANGE AVENUE, LIVINGSTON NJ 07039
Jan Adriaan Haverhals officer: President 110 WHITE ROCK ROAD, APT. 3304, VERONA NJ 07044
Brent W Johnston officer: President C/O MILESTONE SCIENTIFIC INC., 220 SOUTH ORANGE AVENUE SUITE 102, LIVINGSTON NJ 07039
Michael Mcgeehan director C/O MILESTONE SCIENTIFIC INC, LIVINGSTON NJ 07039
Edward J. Zelnick director C/O MILESTONE SCIENTIFIC INC., 220 SOUTH ORANGE AVENUE, LIVINGSTON NJ 07039
Daniel S Goldberger officer: President and CEO 24 CARPENTER ROAD, CHESTER NY 10918
Bp4 S.r.l. director, 10 percent owner, officer: See Remarks CORSO VENEZIA 44, MILAN L6 20121

Milestone Scientific (Milestone Scientific) Headlines